Scale Up

Oct 15, 2016
BioPharm International
Classical production in cell-based systems such as mammalian and bacterial cells requires cell line development and lengthy process development to support scale-up. With plant technology, generic plant bioreactors can be grown rapidly and then transfected with a transient vector based system to produce proteins in days. Large-scale commercial facilities are now available in the US, enabling clinical or commercial production of significant quantities of therapeutic materials within a year.
Jul 14, 2016
This new method uses inter-alpha inhibitors to promote attachment and long-term growth in stem cells.
Jun 01, 2016
BioPharm International
Scale-up of complex, innovative products requires commercialization models that are sustainable.
May 31, 2016
BioPharm sat down with an intellectual property lawyer to examine how companies are protected when they engage in activities where sharing of trade secrets must occur.
Apr 01, 2016
BioPharm International
A modular cell-culture platform demonstrates accelerated process development.
Oct 29, 2015
By BioPharm International Editors
The novel antibody-engineering platform works differently than most of the currently employed antibody-modifying technologies, according to UM Baltimore.
Jul 01, 2015
BioPharm International Multimedia
By BioPharm International Editors
Barry Holtz, Principal, at Holtz Biopharma Consulting, and Klyo Collaborative, spoke with BioPharm International about collaborative success strategies for biopharm companies.
Jun 01, 2015
BioPharm International
Single-use and modular technologies plus continuous manufacturing are increasingly important to biopharma scale-up and tech transfer.
May 01, 2015
BioPharm International
Integrating advances in facility design can meet differing and emerging bioprocessing needs.
Dec 08, 2014
By BioPharm International Editors
Under an NIH contract, Paragon Bioservices will design a manufacturing process for recombinant human rhE-selectin protein.
lorem ipsum